Seres Therapeutics (MCRB) Asset Utilization Ratio (2016 - 2026)

Seres Therapeutics (MCRB) posted Asset Utilization Ratio of 0.01 for Q1 2026, up 60.07% sequentially from 0.01 in Q4 2025.

Seres Therapeutics (MCRB) Asset Utilization Ratio (2016 - 2026) Analysis & Trends

Seres Therapeutics has reported Asset Utilization Ratio for 11 years, with the latest figure at 0.01 in Q1 2026.

Quarterly Asset Utilization Ratio changed N/A year-over-year to 0.01 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01 (changed N/A YoY) and the FY2025 annual result came in at 0.01, changed N/A from the prior year.
Asset Utilization Ratio grew to 0.01 in Q1 2026 per MCRB's latest filing, from 0.01 in the prior quarter.
Over five years, Asset Utilization Ratio peaked at 0.46 in Q2 2022 and troughed at 0.5 in Q3 2024.
A 5-year average of 0.06 and a median of 0.01 in 2023 frame the typical range for Asset Utilization Ratio.
The sharpest annual moves came in 2022 and 2024: Asset Utilization Ratio soared 989.02% in 2022, then plunged 252.24% in 2024.
Over 5 years, Asset Utilization Ratio stood at 0.02 in 2022, then slumped by 86.68% to 0.0 in 2023, then tumbled by 17651.07% to 0.5 in 2024, then soared by 101.11% to 0.01 in 2025, then jumped by 60.07% to 0.01 in 2026.
According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.01, 0.01, and 0.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.38
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.20
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.69
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	0.90
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.13
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.54
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.13
10	Seres Therapeutics	43.87 Mn	43.87 Mn	-	0.02

Download Data